Sientra traded at $0.13 this Tuesday April 9th, increasing $0.02 or 17.97 percent since the previous trading session. Looking back, over the last four weeks, Sientra gained 64.56 percent. Over the last 12 months, its price fell by 90.08 percent. Looking ahead, we forecast Sientra to be priced at 0.13 by the end of this quarter and at 0.11 in one year, according to Trading Economics global macro models projections and analysts expectations.
Sientra, Inc. is a medical aesthetics company. The Company's primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 400 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. Implant Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Company also offers breast tissue expanders for reconstruction procedures predominantly to hospitals and surgery centers, and its BIOCORNEUM scar management products to plastic surgeons, dermatologists and other specialties. The Company's brands also include OPUS, Luxe, Curve, AlloX2, Dermaspan and Softspan.